Answers are grounded in this paper and cite their sources.
T cells expressing higher levels of PD1 which can be modulated by anti-PD1. These data set the scene for clinical evaluation of denosumab use in patients receiving contemporary immune checkpoint blockade.
No takes yet. Share an insight, caveat, or question.
Ahern et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: